Vacinas
Estudos mostram 2 novas plataformas promissoras de vacina contra COVID-19.
10 Mai, 2022 | 14:28hComentário: Studies show promise for 2 new COVID vaccine platforms – CIDRAP
Editorial: Does the World Still Need New Covid-19 Vaccines?
Comentários no Twitter
Efficacy of a plant-based vaccine with adjuvant was 69.5% against symptomatic #COVID19 and 78.8% against moderate-to-severe disease. https://t.co/WH54QWCBdg pic.twitter.com/BiEYpJUD7D
— NEJM (@NEJM) May 4, 2022
ZF2001 vaccine has 87% efficacy against critical or severe #COVID19 for at least 6 months after full vaccination and was safe in large cohort of adults. #IDTwitter https://t.co/wsG0AXqI4Y pic.twitter.com/45fqwVrz9a
— NEJM (@NEJM) May 4, 2022
M-A de estudos randomizados | Associação entre vacinação contra influenza e risco cardiovascular.
4 Mai, 2022 | 13:55hAssociation of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis – JAMA Network Open
Comentário no Twitter
In this meta-analysis, seasonal flu vaccine was associated with a 34% reduced risk of major adverse cardiovascular events in 1 year, with the biggest difference in patients with recent acute coronary syndrome. @WCHResearch @PMunkCardiacCtr https://t.co/SPrXNfMQJS
— JAMA Network Open (@JAMANetworkOpen) April 29, 2022
Revisão | Compreendendo a segurança da vacina e as funções do FDA e do CDC.
2 Mai, 2022 | 14:04hUnderstanding Vaccine Safety and the Roles of the FDA and the CDC – New England Journal of Medicine
Comentário no Twitter
Development and public acceptance of vaccines are crucial for disease control. Cody Meissner, M.D., reviews the process of evaluating vaccine safety and efficacy and factors that advisory bodies consider in making recommendations. https://t.co/ITqpGthoac pic.twitter.com/HTkyAaWvDO
— NEJM (@NEJM) April 28, 2022
Estudo randomizado | Vacina BCG não é efetiva em reduzir o absenteísmo de trabalhadores da atenção à saúde na pandemia de COVID-19.
2 Mai, 2022 | 14:01h
Comentário no Twitter
BCG-CORONA RCT💥 @CMIJournal @MarcBonten
BCG-vaccination of health care worker exposed to #COVID19 patients did NOT reduce unplanned absenteeism nor documented COVID-19 #IDTwitter #MedEd #TwitteRx #MedTwitter https://t.co/yqnpmuy5Y8— Antibiotic Steward Bassam Ghanem🆔🔥 (@ABsteward) April 28, 2022
Estudo de fase 2b | Imunização contra o vírus sincicial respiratório durante a gestação.
29 Abr, 2022 | 14:53hPrefusion F Protein–Based Respiratory Syncytial Virus Immunization in Pregnancy – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário: RSV Prefusion F Protein-Based Immunization Studied in Pregnancy – HealthDay
Comentário no Twitter
In pregnant women, RSVpreF vaccine elicited neutralizing antibody responses with efficient transplacental transfer and without evident safety concerns. https://t.co/r8oktZmBZQ pic.twitter.com/UE7ffxYJW6
— NEJM (@NEJM) April 27, 2022
Estudo de coorte | Incidência da síndrome de Guillain-Barré após vacinação contra Covid-19.
28 Abr, 2022 | 12:07h
Comentário no Twitter
This cohort study of #COVID19 vaccine safety surveillance in the US Vaccine Safety Datalink found a small elevated risk of Guillain-Barré syndrome after Janssen/J&J vaccine but not after mRNA COVID-19 vaccines. @KPDOR https://t.co/TTya5BDqeV
— JAMA Network Open (@JAMANetworkOpen) April 26, 2022
Estudo de coorte | Efetividade de doses de reforço homólogas vs. heterólogas para vacina com SARS-CoV-2 inativado.
27 Abr, 2022 | 16:26hComentários:
COVID-19 vaccine booster strategy: striving for best practice – The Lancet Global Health
Covid-19: Mix and match booster vaccination approach offers best protection, study reports – The BMJ
Comentário no Twitter
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study https://t.co/0k7WlphoDV Heterologous booster provided ⬆️ protection than homologous one, especially when Coronavac vaccine had been used.
— Carlos del Rio (@CarlosdelRio7) April 25, 2022
Estudos destacam o potencial da vacina contra meningite para prevenir a gonorreia.
21 Abr, 2022 | 12:35hComentário: Studies highlight meningitis vaccine’s potential against gonorrhea – CIDRAP
Comunicado de imprensa: Threat of untreatable gonorrhoea could be tackled using an existing meningitis vaccine – The Lancet
Estudo 1: Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study – The Lancet Infectious Diseases (link para o resumo – $ para o texto completo)
Estudo 2: Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study – The Lancet Infectious Diseases (link para o resumo – $ para o texto completo)
Liberadas para estudo clínico as vacinas candidatas da Sinopharm e Sinovac específicas para variante Ômicron da COVID.
21 Abr, 2022 | 11:42hOmicron-specific Sinopharm, Sinovac COVID vaccine candidates cleared for clinical trial – Reuters
Comentário no Twitter
In China, #Omicron-specific vaccines are slated for clinical trials. The vaccine candidates were developed by a Sinopharm subsidiary and Sinovac Biotech. The vaccines are headed to clinical trials in Hong Kong https://t.co/6Y9LsGCKbn
— delthia ricks 🔬 (@DelthiaRicks) April 17, 2022
Revisão sistemática da eficácia e da efetividade da vacina para COVID-19 contra infecção e doença pelo SARS-CoV-2.
21 Abr, 2022 | 11:35h
Comentário no Twitter
🆕💥💥Systematic Review collected efficacy & effectiveness values by vaccine platform, disease outcome, number of doses, & SARS-CoV-2 variants
The spread of the Omicron beginning late 2021 is at least partially driven by reductions in vaccine effectiveness https://t.co/A7hDTQGY4K— Antibiotic Steward Bassam Ghanem🆔🔥 (@ABsteward) April 18, 2022